This randomized controlled trial (RCT) evaluated whether a process with single combined testing of copeptin and troponin at admission in patients with low-to-intermediate risk and suspected acute coronary syndrome (ACS) does not lead to a higher proportion of major adverse cardiac events (MACE) than the current standard process (non-inferiority design).A total of 902 patients were randomly assigned to either standard care or the copeptin group where patients with negative troponin and copeptin values at admission were eligible for discharge after final clinical assessment. The proportion of MACE (death, survived sudden cardiac death, acute myocardial infarction (AMI), re-hospitalization for ACS, acute unplanned percutaneous coronary intervention, coronary artery bypass grafting, or documented life threatening arrhythmias) was assessed after 30 days. Intention to treat analysis showed a MACE proportion of 5.17

作者：Martin, M?ckel；Julia, Searle；Christian, Hamm；Anna, Slagman；Stefan, Blankenberg；Kurt, Huber；Hugo, Katus；Christoph, Liebetrau；Christian, Müller；Reinhold, Muller；Philipp, Peitsmeyer；Johannes, von Recum；Milos, Tajsic；J?rn O, Vollert；Evangelos, Giannitsis

来源：European heart journal 2015 年 36卷 6期